Search
  • 網站搜尋
亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。
返回搜索結果

17S-FD-895: An Improved Synthetic Splice Modulator mirroring FD-895


技術優勢

FDGLY offers the following improvements over known splicing modulators:Improved stability: unlike most of the natural product and synthetic derivatives designed to date FDGLY is bench stable. Easier synthetic preparation: the core unit of FDGLY is prepared from D-glucose streamlining the synthetic preparation. Potent activity in mammalian cell models: properties can be tuned to deliver unique splicing modulatory patterns. Readily addressed medicinal chemical optimization: the use of D-glucose has allowed analog developed to rapidly proceed using other carbohydrate building blocks. The potential for targeting the splicing of specific genes:  the carbohydrate motif allows this derivative, unlike any analog to date, to be subjected to detailed optimization of activity that targets specific genes.


技術應用

FDGLY can be potentially used as a therapeutic agent in clinical use against cancer, as well as an agent to potentiate the effects of known cancer agents. An additional use would be for research, as a molecular probe to modulate splicing.


詳細技術說明

Researchers from UC San Diego have designed a stable splice modulator with improved pharmacological properties. This new analog, described herein as FDGLY, provides several benefits over the known natural product based splice modulators including spliceostatins, pladienolides, and herboxidiene, as well as the current synthetic derivatives approaching or reached IND status including 17S-FD-895, E7107 or 6-deoxypladienolide B. FDGLY is a fully-synthetic spliceosome modulator that mirrors the structural features of FD-895. While FD-895 displays poor pharmacological stability (a factor common to nearly all semi-synthetic or synthetically-derived splice modulators to date), FDGLY displays improved stability in pharmacological buffers, plasma, cell lysates and animal models.


其他

State Of Development

The synthesis of FDGLY has been completed and is currently being used in cell and animal models to complete pharmacological and activity studies. In addition, medicinal chemical efforts are being explored for translation into the clinic for the treatment of cancer. The use of FDGLY is being used to potentiate already known chemotherapeutic agents by using FDGLY to reduce the levels of the proteins targeted by known chemotherapeutics within targeted tumor cells.


Intellectual Property Info

A provisional patent has been submitted and the technology is available to license.


Related Materials

Dhar S, La Clair JJ, León B, Hammons JC, Yu Z, Kashyap MK, Castro JE, Burkart MD. A Carbohydrate-Derived Splice Modulator. J Am Chem Soc. 2016 Apr 20;138(15):5063-8.
Crews LA, Balaian L, Delos Santos NP, Leu HS, Court AC, Lazzari E, Sadarangani A, Zipeto MA, La Clair JJ, Villa R, Kulidjian A, Storb R, Morris SR, Ball ED, Burkart MD, Jamieson CHM. RNA Splicing Modulation Selectively Impairs Leukemia Stem Cell Maintenance in Secondary Human AML. Cell Stem Cell. 2016 Nov 3;19(5):599-612.


Tech ID/UC Case

28845/2016-131-0


Related Cases

2016-131-0


國家/地區

美國

欲了解更多信息,請點擊 這裡
Business of IP Asia Forum
桌面版